Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Cerritos, CA - Oncology Institute, Inc. (NASDAQ:TOI) Director Brad Hively recently acquired shares in the company through a private placement transaction. The acquisition, reported on March 26, 2025, involved the purchase of 9,056 shares of common stock at a price of approximately $1.0417 per share, amounting to a total value of $9,433. The transaction comes as TOI shares, currently trading at $1.14, have shown strong momentum with an 11.42% gain over the past week. According to InvestingPro analysis, the company appears undervalued relative to its Fair Value.
This transaction was part of a securities purchase agreement in which Hively obtained private placement units consisting of two shares of common stock and a common warrant to purchase one share of common stock. The acquisition was approved by the company’s board of directors and deemed an exempt transaction under Rule 16b-3 of the Securities Exchange Act of 1934. The $86M market cap company maintains strong liquidity with a current ratio of 2.15, indicating healthy short-term financial positioning.
Following the transaction, Hively holds 675,809 shares of the Oncology Institute’s common stock directly. The warrants acquired have an exercise price of $0.1250 per share and are subject to certain ownership limits to prevent exceeding a 4.99% beneficial ownership threshold. For deeper insights into TOI’s valuation and 10+ additional ProTips, access the comprehensive Research Report available on InvestingPro.
In other recent news, The Oncology Institute reported its Q4 2024 earnings, revealing a net loss and missing both earnings per share (EPS) and revenue forecasts. The company posted an EPS of -$0.14, falling short of the anticipated -$0.08, and recorded revenue of $100.3 million, below the expected $109.15 million. Despite these misses, the company highlighted a 17% year-over-year increase in consolidated revenue for the quarter and a full-year revenue growth of 21.3% to $393 million. The Oncology Institute also emphasized strategic expansion efforts, including new service contracts in Florida, which are expected to drive future growth. Analysts noted the company’s strategic initiatives, with B. Riley expressing interest in the growth potential of new markets like Florida compared to established ones like California. Furthermore, the company projects 2025 revenue between $460 million and $480 million, with expectations of achieving profitability by Q4 2025. These developments suggest a focus on growth and operational efficiency as the company navigates its financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.